2018-004486-13: A Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Patients With Wet-AMD. |
|
|
| Ongoing | 3 | 656 | Europe | Lucentis®, QL1205-Qilu ranibizumab biosimilar, QL1205, Solution for injection, Lucentis® | Qilu Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd. | Subjects With Wet (neovascular) Age-related Macular Degeneration (wAMD), aged ≥50 years, wet Age-related Macular Degeneration , resulting from damage to the macula, the central portion of the retina caused by the growth of leaky, abnormal blood vessels (choroidal neovascularization), Diseases [C] - Eye Diseases [C11] | | | | |
